Progress: prevention of cervical cancer using the genotyping ampfire? Screening with same-day treatment
Ended Project Grant Awarded Last action
- Award ID
- R44CA272177
- Recipient
-
Atila Biosystems Incorporated UEI YRMLK9B1GHM4
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,031,599
Award facts
- Assistance listing
- 93.393 Cancer Cause and Prevention Research
- Completion date
- Originally
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- In 2018, the world health organization (who) called for action towards achieving the global elimination of cervical cancer. Member states ratified a strategy for achieving this goal in august 2020. The who plan calls for an aggressive approach of vaccination, screening, and treatment of the human papillomavirus (HPV), the single cause of cervical cancer. In low- and middle-income countries (LMIC), which bear 90% of the incidence and mortality of cervical cancer globally, IT is estimated that these goals will not be reached until 2120 - a century from now. One way to shorten this timeline is through HPV self-sampling and immediate treatment for those at the highest risk of developing invasive disease. This will only be possible through a low-cost and effective test that is easy to use in the field, combined with triage strategies that channel women to treatment but avoid unnecessary procedures that drain limited resources. The modified ampfire® HPV genotyping test (atila biosystems, CA) is a new test that identifies 13 high-risk HPV types and stratifies them by oncogenic risk into four groups. Ampfire® relies on loop-mediated isothermal amplification (LAMP) rather than DNA extraction, thus allowing for small-batch processing in 1-2 hours at a low cost per sample. No other HPV test has these characteristics, which allow for the development of same-day screen-and-treat strategies that can triage women at the highest risk, reduce loss to follow-up, and decrease overtreatment. Furthermore, the modified ampfire® has demonstrated high sensitivity in self-collected samples. The purpose of this study is to evaluate the performance of this in the detection of high-grade precancer (cervical intraepithelial neoplasia, grade 2 or higher, or CIN2+). We will also pilot a same-day screen-and-treat strategy using ampfire® and automated visual assessment (AVE), an artificial intelligence triage method based on an assessment of cervical images captured with an ordinary smartphone. Thus, this study will accomplish the following specific aims: specific aim 1: to estimate the test performance of self- and provider- collected modified ampfire® screening platform in honduras; specific aim 2: to evaluate the feasibility of a single visit approach using a self-sampled modified ampfire® screening platform; specific aim 3: evaluate the cost-effectiveness of the same-day screen-and-treat approach using the modified ampfire® test followed by triage with automated visual evaluation (AVE) versus the current strategy in honduras.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $986,359 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,011,310 | |
| Amendment | $1,011,310 | |
| Amendment | $1,011,310 | |
| Original award | $1,011,310 |
Show all 11
Quick answers
Who received award R44CA272177?
R44CA272177 was awarded to Atila Biosystems Incorporated by National Cancer Institute (National Institutes of Health) on September 5, 2022.
How much is award R44CA272177 worth?
$5,031,599 has been obligated on R44CA272177.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award